Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tim Harrison, Giorgio Walter Canonica, Geoffrey Chupp, Jason Lee, Florence Schleich, Tobias Welte, Antonio Valero, Kim Gemzoe, Aoife Maxwell, Sandra Joksaite, Shibing Yang, Peter Howarth, Melissa K. Van Dyke. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020

Member's Comments

No comment yet.

Related content which might interest you: A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study. Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 The patterns of inadequate drug administration in children with asthma: a multi-center retrospective study Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Short-term HRQL deterioration during early-phase COPD exacerbation: a prospective Canadian cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 296s Year: 2005 Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018 Year: 2019 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016 Year: 2017